Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,528.06
(
2.91%
)
US TECH 100
23,068.00
(
3.30%
)
Dow Jones
46,343.58
(
2.49%
)
Brent Oil
103.99
(
-4.22%
)
Bitcoin
67,826.00
(
1.68%
)
News Focus
News Focus
Post# of 257320
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122828
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dangerM post# 224644

Saturday, 04/13/2019 5:13:39 PM

Saturday, April 13, 2019 5:13:39 PM

Post# of 257320
SBPH addendum: Listened to the webcast and studies the CC slides. I don't see any particular reason to be optimistic about the outcomes of the phase-2b trials (just getting underway) other than in showing Inarigivir could have a place as salvage therapy for patients with nuke resistance. But this is not the big market that other HBV players are pursuing.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today